April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Topical Anesthesia in Antiangiogenic Therapy for Retinopathy of Prematurity
Author Affiliations & Notes
  • J. Guerrero-Naranjo
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • M. A. Martinez-Castellanos
    Retina and Vitreous, Association Para Evitar la Ceguera, Mexico, Mexico
  • R. V. Chan
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • V. Morales-Canton
    Retina, Asociacion Para Evitar La Ceguer, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  J. Guerrero-Naranjo, None; M.A. Martinez-Castellanos, None; R.V. Chan, None; V. Morales-Canton, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2810. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Guerrero-Naranjo, M. A. Martinez-Castellanos, R. V. Chan, V. Morales-Canton; Topical Anesthesia in Antiangiogenic Therapy for Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2810.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The aim of the present study is to recorde the use of topical anesthesia in the treatment with antiangiogenic therapy for retinopathy of prematurity

Methods: : We included patients treated in the NICU or in the office. All used tetracaine eye drops before the intravitreal injection of bevacizumab or ranibizumab under aseptic conditions. We measured with the premature infant pain profile (PIPP)

Results: : We included 18 eyes of 9 preterm patients that underwent antiangiogenic therapy for the treatment of retinopathy of prematurity, the PIPP measured in a range from 5 to 12 in a scale 0-21, None of the patients need intrvenous or subcuntaneous sedation, any of the patients presented complications due to anesthesia.

Conclusions: : Topical anesthesia may be an option for the treatment of ROP with antiangiogenic therapy avoiding complications of general anesthesia or sedation.

Clinical Trial: : www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • clinical (human) or epidemiologic studies: systems/equipment/techniques 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.